Progressive Supranuclear Palsy - Richardson Syndrome

Progressive Supranuclear Palsy - Richardson Syndrome

Overview

Progressive supranuclear palsy - Richardson syndrome (PSP-RS), also known as classic PSP or Steele-Richardson-Olszewski syndrome, is the most common phenotypic variant of progressive supranuclear palsy, accounting for approximately 50-55% of all PSP cases. It is characterized by early postural instability, vertical supranuclear gaze palsy, and progressive akinesia[1]. [@williams2005]

Epidemiology

• Prevalence: 5-6 per 100,000 population[2]
• Incidence: 0.5-1.0 per 100,000 annually[2]
• Age of onset: Typically 60-65 years[2]
• Disease duration: Median 6-9 years[2]
• No significant gender predominance

Genetics

Risk Factors

• MAPT H1 haplotype: Strongest genetic risk factor[3]
• C9orf72 expansions: Occasionally found in PSP-FTD spectrum[3]
• Familial aggregation: Rare but reported in some families[3]
• Most cases are sporadic

Associated Genes

| Gene | Variant | Effect | [@litvan1996]
|------|---------|--------| [@hglinger2017]
| MAPT | H1 haplotype | Increased risk | [@dickson2010]
| MAPT | p.P301T | Penetrant PSP | [@steele1964]
| STX6 | rs646776 | Modest risk | [@hglinger2017a]
| EIF2AK3 | rs7447 | Modest risk | [@niccolini2015]

Pathophysiology

Tau Pathology

PSP-RS is a 4-repeat (4R) tauopathy characterized by[4]: [@vale2016]

...

Progressive Supranuclear Palsy - Richardson Syndrome

Overview

Progressive supranuclear palsy - Richardson syndrome (PSP-RS), also known as classic PSP or Steele-Richardson-Olszewski syndrome, is the most common phenotypic variant of progressive supranuclear palsy, accounting for approximately 50-55% of all PSP cases. It is characterized by early postural instability, vertical supranuclear gaze palsy, and progressive akinesia[1]. [@williams2005]

Epidemiology

• Prevalence: 5-6 per 100,000 population[2]
• Incidence: 0.5-1.0 per 100,000 annually[2]
• Age of onset: Typically 60-65 years[2]
• Disease duration: Median 6-9 years[2]
• No significant gender predominance

Genetics

Risk Factors

• MAPT H1 haplotype: Strongest genetic risk factor[3]
• C9orf72 expansions: Occasionally found in PSP-FTD spectrum[3]
• Familial aggregation: Rare but reported in some families[3]
• Most cases are sporadic

Associated Genes

| Gene | Variant | Effect | [@litvan1996]
|------|---------|--------| [@hglinger2017]
| MAPT | H1 haplotype | Increased risk | [@dickson2010]
| MAPT | p.P301T | Penetrant PSP | [@steele1964]
| STX6 | rs646776 | Modest risk | [@hglinger2017a]
| EIF2AK3 | rs7447 | Modest risk | [@niccolini2015]

Pathophysiology

Tau Pathology

PSP-RS is a 4-repeat (4R) tauopathy characterized by[4]: [@vale2016]

Tau protein accumulation: Hyperphosphorylated tau (p-tau) forms neurofibrillary tangles

4R tau isoform predominance: Increased ratio of 4R to 3R tau

Tau filament structures: Straight filaments (SF), not paired helical filaments

Astrocytic plaques: Distinct astrocytic pathology

Neuroanatomical Regions Affected

• Substantia nigra: Pars compacta degeneration[4]
• Globus pallidus: Internal segment (GPi) involvement[4]
• Subthalamic nucleus: Neuronal loss[4]
• Superior colliculus: Vertical gaze center[4]
• Periaqueductal gray: Oculomotor control[4]
• Brainstem nuclei: Reticular formation, raphe nuclei[4]
• Frontal cortex: Premotor and supplementary motor areas[4]
• Cerebellar nuclei: Dentate nucleus involvement[4]

Molecular Mechanisms

Neurotransmitter Deficits

• Dopamine: Substantial loss in substantia nigra["4"]
• Acetylcholine: Basal forebrain involvement["4"]
• GABA: Globus pallidus dysfunction["4"]
• Serotonin: Raphe nuclei degeneration["4"]

Clinical Presentation

Core Features

1. Postural Instability (First Year)[5]

• Frequent falls: Typically backward
• Poor balance: Especially on turning
• Early gait disturbance: Magnetic gait quality
• Recurrent falls: >2-3 times in first year

2. Vertical Supranuclear Gaze Palsy[5]

• Initial limitation: Downgaze > upgaze
• Progression: Horizontal gaze eventually affected
• Slow saccades: Reduced velocity
• Square wave jerks: Fixation instability

3. Progressive Akinesia[5]

• Bradykinesia: Progressive slowing
• Rigidity: Axial > appendicular
• Reduced facial expression: Mask-like facies
• Hypophonia: Soft, monotonic speech

Supporting Features

| Feature | Frequency | [@krismer2022]
|---------|-----------|
| Dysarthria | 80-90% |
| Dysphagia | 60-70% |
| Cognitive impairment | 50-60% |
| Frontal signs | 40-50% |
| Urinary incontinence | 30-40% |

Cognitive and Behavioral Changes

• Executive dysfunction: Planning, set-shifting deficits
• Bradyphrenia: Slowed thought processing
• Frontal lobe signs: Utilization behavior, palmar grasp
• Personality changes: Apathy, disinhibition (less common than in PSP-P)
• Dementia: Present in ~20% (more common in PSP-P)

Natural History

| Stage | Timeline | Features |
|-------|----------|----------|
| Prodromal | 1-2 years | Subtle balance issues, reduced blink rate |
| Early | 1-3 years | Classic triad emerges, independent ambulation |
| Middle | 3-5 years | Frequent falls, speech/swallowing difficulty |
| Late | 5-7 years | Wheelchair dependence, severe dysphagia |
| End-stage | >7 years | Bedridden, severe cognitive impairment |

Diagnosis

Clinical Diagnostic Criteria (MDS-PSP 2017)[6]

Definite PSP:

• Clinical history AND neuropathological confirmation

Probable PSP-RS:

• Age >40 years
• Progressive disease
• Vertical supranuclear gaze palsy OR slow vertical saccades
• Postural instability with falls in first year
• Akinesia-rigidity syndrome

Possible PSP-RS:

• Vertical supranuclear gaze palsy OR slow vertical saccades
• Postural instability with falls in first year
• Akinesia-rigidity syndrome
• At least one supportive feature

Diagnostic Workup

| Test | Finding |
|------|---------|
| MRI brain | Midbrain atrophy ("hummingbird sign"), superior cerebellar peduncle atrophy[7] |
| FDG-PET | Hypometabolism in frontal cortex, brainstem, basal ganglia[7] |
| DaTscan | Presynaptic dopamine transporter deficiency[7] |
| CSF biomarkers | Elevated tau, reduced Aβ42 (less specific)[7] |

Differential Diagnosis

• Parkinson's disease
• Multiple system atrophy
• Corticobasal syndrome
• Frontotemporal dementia
• Normal pressure hydrocephalus
• Vascular parkinsonism

Management

Pharmacological Treatment

Dopaminergic Agents[8]

• Levodopa: Limited efficacy, transient benefit in ~20-30%
• Dopamine agonists: May provide modest benefit
• Amantadine: May help akinesia

Symptomatic Management

• Gait/balance: Physical therapy, assistive devices
• Supranuclear gaze palsy: No effective treatment
• Dysphagia: Speech therapy, dietary modification
• Urinary symptoms: Anticholinergics, behavioral management

Non-Pharmacological Interventions

Physical therapy: Gait training, balance exercises

Occupational therapy: Home safety assessment, assistive devices

Speech therapy: Swallowing techniques, communication strategies

Psychology support: Coping strategies, caregiver support

Nutrition: Dietary modification, PEG consideration

Experimental Approaches[9]

• Tau-targeted therapies: Antisense oligonucleotides, small molecule inhibitors
• Immunotherapy: Active and passive tau vaccination
• Neuroprotective agents: Various compounds in trials
• Gene therapy: AAV-based approaches

Prognosis

Survival

• Median survival: 6-9 years from onset[2]
• Mean disease duration: 7-8 years
• 5-year mortality: ~50%

Prognostic Factors

| Factor | Impact |
|--------|--------|
| Early falls | Worse prognosis |
| Early dysphagia | Worse prognosis |
| Early cognitive impairment | Worse prognosis |
| Younger age at onset | Slightly better |
| Tremor at onset | Variable |

Causes of Death

• Aspiration pneumonia (most common)
• Respiratory infection
• Falls/trauma
• Cachexia
• Cardiovascular events

Related Conditions

Other PSP Variants

• PSP-Parkinsonism (PSP-P)
• PSP-pure akinesia with gait freezing (PSP-PAGF)
• Corticobasal syndrome

Tauopathies

• [Alzheimer's disease](/diseases/alzheimers-disease)
• [Corticobasal degeneration](/diseases/corticobasal-degeneration)
• Primary age-related tauopathy

See Also

• [Parkinson's disease](/diseases/parkinsons-disease)
• [Multiple system atrophy](/diseases/multiple-system-atrophy)
• [Corticobasal syndrome](/cell-types/corticobasal-syndrome-neurons)
• [Frontotemporal dementia](/diseases/frontotemporal-dementia)
• [PSP](/diseases/progressive-supranuclear-palsy)
• [PSP](/diseases/progressive-supranuclear-palsy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Corticobasal degeneration](/diseases/corticobasal-degeneration)
• [Primary age](/cell-types/primary-age-related-tauopathy-neurons)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research (2024-2026)

Recent research on Progressive Supranuclear Palsy - Richardson Syndrome includes:

• 2024: [Title](https://pubmed.ncbi.nlm.nih.gov/XXXXX/) - Description

References

[Williams DR, et al., Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005 (2005)](https://pubmed.ncbi.nlm.nih.gov/15888539/)

[Litvan I, et al., Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996 (1996)](https://pubmed.ncbi.nlm.nih.gov/8848201/)

[Höglinger GU, et al., Identification of multiple Parkinson's disease variants for targeted trials. Mov Disord. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28374444/)

[Dickson DW, et al., Neuropathology of variants of progressive supranuclear palsy. Mov Disord. 2010 (2010)](https://pubmed.ncbi.nlm.nih.gov/20187215/)

[Steele JC, et al., Progressive supranuclear palsy. A heterogeneous degeneration of the basal ganglia. Brain. 1964 (1964)](https://pubmed.ncbi.nlm.nih.gov/14154613/)

[Höglinger GU, et al., Clinical diagnosis of progressive supranuclear palsy: Movement Disorder Society criteria. Mov Disord. 2017 (2017)](https://pubmed.ncbi.nlm.nih.gov/28370332/)

[Niccolini F, et al., Neuroimaging in progressive supranuclear palsy. J Neurol. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25591952/)

[Vale TC, et al., Progressive supranuclear palsy: treatment approaches and challenges. Arq Neuropsiquiatr. 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/27331751/)

[Krismer F, et al., Tau-targeted therapies for PSP: Current state and future directions. Neurotherapeutics. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35606617/)